Stage 3 breast cancer means the cancer has grown beyond the breast into nearby tissues or lymph nodes but has not spread to distant organs. It’s considered locally advanced, sitting between earlier stages (where the tumor is confined to the breast) and stage 4 (where cancer has reached the bones, lungs, liver, or brain). The 5-year relative survival rate for regional breast cancer, which includes most stage 3 cases, is 86.3% based on National Cancer Institute data from 2013 to 2019.
What Makes It Stage 3
Breast cancer staging uses three factors: tumor size (T), lymph node involvement (N), and whether the cancer has metastasized to distant sites (M). Stage 3 covers a range of scenarios, all sharing one theme: the cancer is extensive locally but hasn’t traveled far. The specific substages break down like this:
- Stage 3A: The tumor may be larger than 5 centimeters with cancer in one to three nearby lymph nodes, or the tumor can be any size with cancer found in four to nine lymph nodes under the arm or near the breastbone.
- Stage 3B: The cancer has grown into the chest wall or skin of the breast, possibly causing swelling or ulceration. It may also involve nearby lymph nodes. All inflammatory breast cancers, a fast-growing type that causes redness, swelling, and warmth across the breast, are classified as at least stage 3B regardless of tumor size.
- Stage 3C: Cancer has spread to 10 or more lymph nodes under the arm, or to lymph nodes above or below the collarbone, or to nodes both under the arm and near the breastbone. The tumor itself can be any size.
How Treatment Typically Works
Stage 3 breast cancer almost always requires a combination of chemotherapy, surgery, and radiation. What sets it apart from earlier stages is the sequencing: most patients start with chemotherapy before surgery, not after. This approach, called neoadjuvant chemotherapy, serves two purposes. First, it can shrink a large tumor enough to make surgery possible when it otherwise wouldn’t be. Second, it gives doctors a real-time window into how the cancer responds to treatment. If a tumor isn’t shrinking, the treatment plan can be adjusted early rather than discovered months later.
In tumors that were already operable, pre-surgery chemotherapy also increases the chance of keeping the breast. Studies show it raises breast conservation rates by 7% to 12%, turning some patients who would have needed a full mastectomy into candidates for a lumpectomy instead.
Surgery Options
After chemotherapy shrinks the cancer, surgery removes whatever remains. For some stage 3 patients, a lumpectomy (removing the tumor and a margin of surrounding tissue) is possible. But a mastectomy, removing the entire breast, is more common at this stage, particularly if the cancer involves multiple areas of the breast, if the tumor is large relative to breast size, or if it has grown into the chest wall or skin.
If you have a lumpectomy, radiation therapy afterward is standard. That typically means daily treatments five days a week for up to six weeks. After the tissue is removed, pathologists examine the edges of the specimen. If cancer cells are found at those margins, additional surgery may be needed to ensure everything has been cleared.
Why Radiation Is Part of the Plan
For stage 3, radiation is recommended even after a full mastectomy. This is different from earlier stages, where post-mastectomy radiation is sometimes optional. Clinical guidelines are clear: patients who presented with stage 3 disease and received chemotherapy before surgery should get radiation regardless of how well the chemotherapy worked. Even if imaging and pathology show a complete response to chemo, radiation still reduces the risk of the cancer returning in the chest wall or nearby lymph nodes and improves long-term survival. Decades of clinical trials have consistently confirmed this benefit for patients with large tumors or positive lymph nodes.
Lymph Node Surgery
Because stage 3 almost always involves lymph nodes, the surgical approach to the armpit (axilla) is more extensive than in early breast cancer. For patients who had confirmed cancer in multiple lymph nodes before treatment, a full axillary lymph node dissection is typically recommended. This means removing a larger group of nodes rather than sampling just a few.
There is one exception. If chemotherapy eliminates all palpable disease in the armpit, and if the original lymph node involvement was limited, some patients may qualify for a less invasive sentinel lymph node biopsy instead. However, for patients who still have palpable lymph node disease after chemotherapy, or who presented with extensive nodal involvement (the N2 or N3 categories that define stages 3B and 3C), full dissection remains the standard. This more extensive surgery carries a higher risk of side effects like arm swelling (lymphedema), which your surgical team will discuss beforehand.
The Full Treatment Timeline
From diagnosis to completing active treatment, stage 3 breast cancer typically takes the better part of a year, and sometimes longer. Here’s what a common timeline looks like:
- Biopsy to starting chemotherapy: 1 to 4 weeks
- Pre-surgery chemotherapy: 3 to 6 months
- Chemotherapy to surgery: 3 to 6 weeks
- Recovery and radiation: 3 to 6.5 weeks of daily treatments
Beyond that initial stretch, many patients continue some form of maintenance therapy. Depending on the cancer’s biology, this could include targeted therapy for up to three years or hormone-blocking medication for up to ten years. These ongoing treatments are typically oral pills or periodic injections, not the intensive infusion chemotherapy of the first several months.
What Affects the Outlook
The 86.3% five-year relative survival figure is a population average. Individual outlook depends on several factors. The cancer’s biological subtype matters enormously: hormone receptor-positive cancers tend to respond well to years of hormone therapy, while HER2-positive cancers benefit from targeted drugs that have dramatically improved outcomes over the past two decades. Triple-negative breast cancer, which lacks these receptors, is more challenging to treat but often responds strongly to chemotherapy.
How the cancer responds to pre-surgery chemotherapy is also a powerful predictor. Patients who achieve a pathologic complete response, meaning no detectable cancer remains in the breast or lymph nodes at the time of surgery, generally have significantly better long-term outcomes than those with residual disease. Age, overall health, and the specific substage (3A vs. 3C, for instance) all play roles as well. A stage 3A diagnosis with four positive lymph nodes carries a different prognosis than stage 3C with cancer above the collarbone.
Stage 3 is serious, but it is treated with curative intent. The combination of systemic therapy, surgery, and radiation targets the disease from multiple angles, and the majority of patients survive well beyond five years.